ALCJ (ALCJ) News
Track canonical SquawkNews coverage tagged to ALCJ, ALCJ. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
CROSSJECT (ALCJ) Adds Three Executives to Board for Scale-Up
CROSSJECT appointed Olivier Lacombe, Didier Morin and Lionel Seltz to its Executive Board, effective immediately, to support industrial scale-up and U.S. commercialization prep.Material DetailsContext by AI AnalystThis m
NEWS | Sep 25, 2026, 05:32 AM UTC
L
CROSSJECT (ALCJ) H1: Cash €12.3M, Adjusted Net Debt €7.8M
CROSSJECT reported H1 2026 results: cash €12.3M after a €15M capital raise, shareholders’ equity €3.0M, adjusted net financial debt €7.8M, and net loss €8.6M. BARDA contract funding was extended to $48.0M through 2030 po
NEWS | Sep 25, 2026, 05:32 AM UTC
L
CROSSJECT strengthens its governance for the industrial and commercial deployment phase
DIJON, FRANCE, September 25, 2026 — 07h30 (CEST) — CROSSJECT (ISIN: FR0011716265; Euronext Growth: ALCJ), a Specialty Pharma company developing innovative solutions for emergency situations based on its proprietary ZENEO
NEWS | Sep 25, 2026, 05:32 AM UTC
L
CROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial Structure
Cash and cash equivalents of €12.3 million as of June 30, 2026, a 2.4-fold increase compared to December 31, 2025 (€5.1 million), following the €15 million capital increase completed in May.Shareholders’ equity returned
NEWS | Sep 25, 2026, 05:32 AM UTC